Cellectis SA (CLLS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $118.86M
Last updated: Nov 17, 2026 at 4:10 PM ET
Cellectis SA (CLLS) Statistics
Cellectis SA (CLLS) has a market cap of $118.86M and an enterprise value of $35.35M. It kept -474.44% of revenue as net income over the last 12 months. Revenue fell 64.32% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 70.26% below the market cap, as cash exceeds debt.
| Market Cap | $118.86M |
|---|---|
| Enterprise Value | $35.35M |
| Latest price (Nov 17, 2026) | $1.06 |
Key Dates
| Last Earnings Date | Nov 12, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 4.0x. Its year-end P/S ranged from 4.3x to 251.1x from 2016 to 2025.
| P/S Ratio | 4.0x |
|---|---|
| Forward P/S | 2.3x |
Price Statistics
The stock is down 72.82% over 52 weeks and trades 22.06% below its 50-day average.
| Beta (1Y) | 2.36 |
|---|---|
| 52-Week Change | -72.82% |
| 1-Month Change | +14.53% |
| 3-Month Change | -66.56% |
| 6-Month Change | -70.80% |
| 5-Year Change | -89.96% |
| 10-Year Change | -93.89% |
| Total Return (1Y) | -72.82% |
| Total Return (3Y CAGR) | -28.74% |
| Total Return (5Y CAGR) | -34.97% |
| Return vs SPY (1Y) | -85.77% |
| Max Drawdown (1Y) | -82.70% |
| Max Drawdown (3Y) | -82.70% |
| Sharpe Ratio (1Y) | -1.42 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $1.36 |
| 200-Day Average | $2.89 |
| 52-Week Range | $0.88 to $5.45 |
| RSI (14 Days) | 43.1 |
| Average Volume (20 Days) | 81.21K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.15x current liabilities.
| Current Ratio | 1.15x |
|---|---|
| Quick Ratio | 1.15x |
| Interest Coverage | -16.16x |
Returns and Efficiency
Return on invested capital is -287.29% over the last 12 months, against a 5-year average of -44.77%.
| Return on Assets (ROA) | -59.70% |
|---|---|
| Return on Invested Capital (ROIC) | -287.29% |
| ROE (5Y Average) | -71.82% |
| ROA (5Y Average) | -24.20% |
| ROIC (5Y Average) | -44.77% |
| Asset Turnover | 0.10x |
| Receivables Turnover | 3.02x |
Scores
CLLS has an Altman Z-Score of -3.95, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -3.95 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $26.85M over the last 12 months.
| Revenue | $26.85M |
|---|---|
| Revenue Growth (YoY) | -64.32% |
| Gross Profit | $14.90M |
| Operating Income | -$127.41M |
| Pretax Income | -$131.18M |
| Net Income | -$127.41M |
| EBITDA | -$117.57M |
| Reported EPS (TTM) | -$0.63 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $146.71M |
|---|---|
| Total Debt | $63.20M |
| Net Cash | $83.51M |
| Working Capital | $21.89M |
| Shareholder Equity | -$17.63M |
| Tangible Book Value | -$18.44M |
| Total Assets | $213.43M |
| Total Liabilities | $231.06M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.40M of capital spending, operating cash flow left -$58.89M of free cash flow.
| Operating Cash Flow | -$56.49M |
|---|---|
| Capital Expenditures | $2.40M |
| Free Cash Flow | -$58.89M |
| FCF Per Share | -$0.81 |
| Depreciation and Amortization | $45.70M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -474.46%.
| Gross Margin | 55.48% |
|---|---|
| Operating Margin | -474.46% |
| Pretax Margin | -488.49% |
| Net Margin | -474.44% |
| EBITDA Margin | -437.80% |
| FCF Margin | -219.30% |
Growth
Revenue grew 56.12% a year over 3 years.
| Revenue Growth (3Y CAGR) | +56.12% |
|---|---|
| Revenue Growth (5Y CAGR) | -0.27% |
Dividends and Yields
CLLS does not pay a dividend. Its free cash flow yield is -55.17%.
| FCF Yield | -55.17% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 4 similar companies, CLLS has the 4th highest P/S.
P/S RatioPeer median 28.7x
ROICPeer median -46.74%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -99.55%
| P/S Ratio | 4.0x vs 28.7x median |
|---|---|
| ROIC | -287.29% vs -46.74% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -64.32% vs -99.55% median |
Analyst Forecast
Consensus estimates put revenue growth at 22.93% a year over the next 5 fiscal years.
| Revenue Growth Forecast (5Y CAGR) | +22.93% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CLLS
What is CLLS's market cap?
Cellectis SA has a market cap of $118.86M. Its enterprise value, which adds debt and subtracts cash, is $35.35M.
How many shares of CLLS are outstanding?
Cellectis SA has 100.71M shares outstanding. The count is up 0.39% from a year earlier.
Does CLLS pay a dividend?
No. Cellectis SA does not pay a dividend.
How much debt does CLLS have?
Cellectis SA has $63.20M of total debt and $146.71M of cash and equivalents, a net cash position of $83.51M.
CLLS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors